Cardiovascular Diseases (CVD)
Conditions
Keywords
Antihyperlipidemic, Cardiovascular diseases, Rosuvastatin
Brief summary
The goal of this clinical trial is to study the efficiency and safety of using combinations of antihyperlipidemic agents with a single drug to treat cardiovascular diseases. The main questions it aims to answer are: * Which approach is more effective rosuvastatin monotherapy or rosuvastatin ezetimibe combination antihyperlipidemic for patients with cardiovascular diseases (CVDs)? * What medical problems do participants could when taking antihyperlipidemic drugs? Researchers will compare rosuvastatin 20 mg or rosuvastatin ezetimibe10/10mg to see the effectiveness and safety of these drugs in patients with CVDs. Participants will: * Patients will randomize to either rosuvastatin 20 mg or rosuvastatin ezetimibe10/10mg. * Patients will be followed up to 12 weeks after starting treatment. * All the patients will be subjected to: Full sheet taking, including detailed history and diagnosis of the case, Baseline Aspartate aminotransferase (AST) and Alanine Aminotransferase (ALT) tests& after 24 weeks of treatment, Lipid Profile, creatine kinase (CK) test, Creatine kinase-MB (CK-MB) test.
Interventions
DRUGrosuvastatin drug
Patients randomized to receive rosuvastatin 20 mg
COMBINATION_PRODUCTPatients received rosuvastatin ezetimibe10/10mg
Patients received rosuvastatin ezetimibe10/10mg
Sponsors
Beni-Suef University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
Adults above 18 years, Dyslipidemic patients
Exclusion criteria
Young people under 18 years old pregnant women lactating women Children Hypersensitivity Renal failure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Creatine Kinase | at baseline and after 12 weeks |
Countries
Egypt
Outcome results
None listed